OncoMatch/Clinical Trials/NCT07223034
A Study of 177Lu-PSMA-617 in People With Gliomas
Is NCT07223034 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Temozolomide and 177Lu-PSMA-617 for glioma.
Treatment: Temozolomide · 177Lu-PSMA-617 — The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Radioligand therapy
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Required: PSMA (FOLH1) expression (positive)
Required: IDH1 wild-type
Disease stage
Required: Stage GRADE 2, GRADE 3, GRADE 4
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care therapy for glioma
Cannot have received: bevacizumab (bevacizumab)
Cannot have received: radionuclide therapy (radium223, strontium89, samarium153)
Cannot have received: radiation therapy to >25% of skeleton
Cannot have received: investigational agents
Lab requirements
Blood counts
total white blood count > 3.0 k/mcl; anc ≥ 1.5 k/mcl; platelets ≥ 100 k/mcl; hemoglobin ≥ 9 g/dl
Kidney function
serum creatinine level < 1.5 x uln or egfr > 60 ml/min
Liver function
alt and ast ≤ 2.5 x uln; albumin > 2 g/dl; bilirubin < 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07223034 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bevacizumab, radionuclide therapy, radiation therapy to >25% of skeleton disqualifies patients from enrollment.
Does this trial require FOLH1?
Yes, FOLH1 expression is a required biomarker for enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage GRADE 2 or GRADE 3 or GRADE 4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify